Stephen Reduces Stake in Cardinal Health,

Trending News 🌥️

The company operates in two segments: Pharmaceutical and Medical. Their Pharmaceutical segment distributes generic and brand-name drugs, as well as over-the-counter medications, to wholesalers, retailers, hospitals, and other healthcare providers. The Medical segment distributes medical and surgical products and provides services to healthcare providers to improve safety in healthcare settings. Cardinal Health ($NYSE:CAH)’s stock is traded on the New York Stock Exchange (NYSE) under the symbol CAH. They are committed to delivering value to their customers, shareholders, employees and the communities they serve.

Their long-term outlook remains positive as they continue to develop innovative solutions to help healthcare providers improve patient care and reduce costs. Stephen Inc.’s decision to reduce their ownership in Cardinal Health reflects their confidence in the company’s long-term prospects.

Price History

On Monday, news sentiment surrounding Cardinal Health, Inc. was mostly positive. Stephen Inc. announced that they had reduced their stake in the company. Despite this news, the stock opened at $76.0 and closed at $75.5, a slight decrease of 0.4% from its last closing price of $75.8. The reduction of Stephen Inc.’s stake in Cardinal Health, Inc. was a surprise to many investors, as the company has seen a steady growth in recent months. It is unclear why Stephen Inc. decided to reduce their stake, but the news has had a small impact on the stock price. Cardinal Health, Inc. is a healthcare services company that operates in the pharmaceutical and medical products industries.

It serves as a wholesale distributor of pharmaceuticals and other related products, as well as provides services such as inventory management and logistics. The company has seen steady growth in recent years, due to an increased demand for its products and services. Despite the reduction of Stephen Inc.’s stake, investors remain upbeat about the future of Cardinal Health, Inc. The company has a strong presence in the healthcare industry and is well-positioned to capitalize on the growing demand for its products and services. As such, investors are optimistic that the company can continue to see steady growth in the coming months. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Cardinal Health. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Cardinal Health. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Cardinal Health. More…

Key Ratios Snapshot

Some of the financial key ratios for Cardinal Health are shown below. More…

VI Analysis

According to VI Star Chart, the company is strong in terms of asset strength, medium in terms of growth, profitability, and weak in dividend. Its high health score of 8/10 indicates that it has the capacity to safely ride out any crisis without the risk of bankruptcy. CARDINAL HEALTH has been classified as a ‘rhino’, which is a type of company that has achieved moderate revenue or earnings growth. Investors interested in such a company should be aware that CARDINAL HEALTH is a company that has established itself as a reliable and stable business. It may offer investors a steady stream of income and capital growth over the long term. The company has good financials and a sound balance sheet, indicating that it can easily weather any economic downturns. Furthermore, investors interested in CARDINAL HEALTH should also consider its long-term potential, due to the company’s focus on innovation and its ability to remain competitive in the industry. Overall, CARDINAL HEALTH is a strong long-term investment choice for those investors looking to build a portfolio of reliable businesses that are capable of providing consistent returns over time. With its strong fundamentals and attractive long-term potential, CARDINAL HEALTH is an attractive option for investors looking for a safe bet. More…

VI Peers

Its competitors are AmerisourceBergen Corp, McKesson Corp, and Sigma Healthcare Ltd.

– AmerisourceBergen Corp ($NYSE:ABC)

AmerisourceBergen Corp is a drug wholesaler that was founded in 1985. The company has a market cap of 32.4B as of 2022 and a return on equity of 417.0%. AmerisourceBergen Corp distributes prescription drugs and other healthcare products and services to healthcare providers and pharmaceutical companies. The company operates in two segments, Pharmaceutical Distribution and Other.

– McKesson Corp ($NYSE:MCK)

McKesson Corp is a healthcare services and information technology company. It has a market cap of 55.96B as of 2022 and a Return on Equity of -74.43%. The company provides a range of services and products to healthcare providers, payers, and consumers. These services and products include prescription drugs, medical supplies, and software and technology solutions.

– Sigma Healthcare Ltd ($ASX:SIG)

Sigma Healthcare Ltd is a pharmaceutical company with a market cap of 683.23M as of 2022 and a ROE of 0.46%. The company manufactures and distributes a range of prescription and over-the-counter medicines, medical devices, and other healthcare products.

Summary

Analysts suggest this could indicate a shift in the company’s overall strategy or that the firm may be looking to invest in other areas. Cardinal Health has been a major player in its industry for many years, providing discount pharmacy services and specialty drugs to millions of customers worldwide. Despite the recent news, the company’s fundamentals remain solid, with analysts citing its strong balance sheet, solid cash flow and robust earnings growth as reasons for optimism. With its strong fundamentals, investors may want to consider adding Cardinal Health to their portfolios.